Evaluation of the need for dosing adaptations in obese patients for surgical antibiotic prophylaxis: a model-based analysis of cefazolin pharmacokinetics.

ABSTRACT:

Background

Cefazolin is used as a prophylactic antibiotic to reduce surgical site infections (SSIs). Obesity has been identified as a risk factor for SSIs. Cefazolin dosing recommendations and guidelines are currently inconsistent for obese patients. As plasma and target-site exposure might differ, pharmacokinetic data from the sites of SSIs are essential to evaluate treatment efficacy: these data can be obtained via tissue microdialysis. This analysis was designed to evaluate the need for dosing adaptations in obese patients for surgical prophylaxis.

Methods

Data from 15 obese (BMI_median = 52.6 kg m^-2) and 15 age- and sex-matched nonobese patients (BMI_median = 26.0 kg m^-2) who received 2 g cefazolin i.v. infusion for infection pro

SUBMITTER: Bindellini D 

PROVIDER: S-EPMC11947583 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature